Aim. To study clinical effectiveness of a calcium antagonist nifedipine SR in patients with various clinical variants of Stage I-II arterial hypertension (AH), aged over 60 years. Material and methods. An open, prospective, 48-week study included 48 patients with Stage I-II AH (mean age 66,15±4,81 years). Participants with systolo-diastolic AH (SDAH) and isolated systolic AH (ISAH) received nifedipine SR (Cordaflex RD) (40 mg/d). Treatment effectiveness was assessed by the dynamics of office blood pressure (BP) measurements and 24-hour BP monitoring (BPM). Organo-protection was assessed by echocardiography parameters and microalbuminuria (MAU) level. Vasoprotection was assessed by volume sphygmography and endothelial dysfunction parameters. Results. Nifedipine SR therapy normalized circadian BP profile, reduced pressure load parameters and pulse BP, improved systolic and diastolic function, facilitated myocardial hypertrophy regression, and decreased the number of MAU individuals in both groups, especially in those with ISAH. In addition, nifedipine SR facilitated arterial remodeling regression in elderly patients: in ISAH participants, its effect was mostly targeted at elastic vessels; in SDAH individuals, on muscular vessels and endothelial dysfunction correction. Conclusion. Nifedipine SR therapy for 48 weeks demonstrated stable antihypertensive and organo-protective effects in elderly patients.

Aim. To study clinical effectiveness of a calcium antagonist nifedipine SR in patients with various clinical variants of Stage I-II arterial hypertension (AH), aged over 60 years.Material and methods. An open, prospective, 48-week study included 48 patients with Stage I-II AH (mean age 66,15 +/- 4,81 years). Participants with systolo-diastolic AH (SDAH) and isolated systolic AH (ISAH) received nifedipine SR (Cordaflex RD) (40 mg/d). Treatment effectiveness was assessed by the dynamics of office blood pressure (BP) measurements and 24-hour BP monitoring (BPM). Organo-protection was assessed by echocardiography parameters and microalbuminuria (MAU) level. Vasoprotection was assessed by volume sphygmography and endothelial dysfunction parameters.Results. Nifedipine SR therapy normalized circadian BP profile, reduced pressure load parameters and pulse BP, improved systolic and diastolic function, facilitated myocardial hypertrophy regression, and decreased the number of MAU individuals in both groups, especially in those with ISAH. In addition, nifedipine SR facilitated arterial remodeling regression in elderly patients: in ISAH participants, its effect was mostly targeted at elastic vessels; in SDAH individuals, on muscular vessels and endothelial dysfunction correction.Conclusion. Nifedipine SR therapy for 48 weeks demonstrated stable antihypertensive and organo-protective effects in elderly patients.

Aim. To study arterial structure and function in patients aged over 60 years with Stage I-II isolated systolic and systolo-diastolic arterial hypertension (ISAH, SDAH). To assess vasoprotective effects of 24-week treatment with a calcium antagonist nifedipine (Cordaflex (R) RD).Material and methods. This prospective 24-week study included 48 patients with Stage I-II AH, aged over 60 years. SDAH and ISAH patients were administered Cordaflex (R) RD (40 mg/d), and treatment effectiveness was assessed by office blood pressure (BP) dynamics. Vasoprotective effects of the medication were assessed by volume sphygmography and echocardiography dynamics.Results. Cordaflex (R) RD demonstrated not only good anti hypertensive effects, but also improved arterial elasticity, reducing pulse wave velocity (PWV) in various vessel types. In ISAH patients, its effects were maximal for elastic type vessels, and in SDAH individuals - for muscular type vessels. The medication reduced intima-media thickness (IMT) increase and improved endothelial function.Conclusion. In ISAH and SDAH patients aged over 60 years, Cordaflex (R) RD improved endothelial function and arterial wall elasticity, providing vasoprotection and target BP level achievement.

Aim. To study antihypertensive and organo-protective effects of a calcium antagonist (CA), controlled-release (CR) nifedipine, in patients over 60 years with Stage I-II isolated systolic and systolo-diastolic arterial hypertension (ISAH, SDAH).Material and methods. This 24-week open prospective Study included 48 patients aged over 60 years with Stage I-II AH. SDAH and ISAH participants received nifedipine SR in the dose of 40 mg/d. Treatment effectiveness was assessed by dynamics of office blood pressure (BP) and 24-hour BP monitoring (BBP) parameters. Organo-protective effect was assessed by dynamics of echocardiography parameters and microalbuminuria (MAU) levels.Results. Nifedipine SR therapy was associated with substantial BP reduction and improved circadian BP profile in all participants; reduced myocardial hypertrophy in elderly people; normalisation of left ventricular (LV) diastolic function and decreased number of patients with MAU in both groups, especially among those with ISAH.Conclusion. Complex assessment of nifedipine SR clinical effectiveness in ISAH and SDAH patients aged over 60 years demonstrated multiple effects on AH-related parameters and improved circulatory functioning in elderly patients. Nifedipine SR is a medication of choice in ISAH patients.